Asthma And COPD Market Outlook: Market Analysis Of Future Growth And Leading Players By Sector : Market Research Report

Asthma And COPD Market Outlook: Market Analysis Of Future Growth And Leading Players By Sector

Published: Jan. 1, 2005 - 110 Pages

Table of Contents

The Asthma and COPD Market Outlook: Market

analysis of future growth and leading players by sector

Executive summary 10

Epidemiology analysis 10

Global asthma/COPD market analysis 11

First/second-line treatment market analysis 12

Third-line asthma treatments market analysis 13

Leading players in the asthma/COPD market 14

Chapter 1 Epidemiology analysis 16

Summary 16

Introduction 17

Disease description 17

Asthma 17

Chronic Obstructive Pulmonary Disease 18

Disease classification 18

Asthma 18

COPD 20

Current and future prevalence of asthma/COPD 20

Asthma 20

COPD 23

Diagnosis 26

Asthma 26

COPD 28

Current and future treatment patterns 28

4

Chapter 2 Global asthma/COPD market

analysis 34

Summary 34

Introduction 35

History of asthma drugs 35

Current growth drivers 36

SABA/LABA treatments 37

ICS 37

Xanthines 38

Oral corticosteroids 38

Combination therapies 39

Anticholinergics and leukotriene antagonists 39

Future growth drivers 40

Monoclonal antibodies 40

Anti-muscarinics 40

Chapter 3 First and second-line therapies:

Beta-2 agonists, ICS and

combination ICS/LABA drugs 42

Summary 42

Introduction 43

First and second-line treatment categories and sales 43

Company market share 44

Brand market share and sales 46

SABA/LABA treatments 51

Brand analysis 51

Serevent (salmeterol xinfoate) 51

Xopenex (levalbuterol) 53

Ventolin (salbutamol/albuterol) 55

Foradil (formoterol fumarate) 56

ICS treatments 57

Brand analysis 57

Flixotide/Flovent (fluticasone propionate) 58

Pulmicort (budesonide) 59

LABA/ICS combination treatments 61

Brand analysis 61

Seretide/Advair (fluticasone propionate and salmeterol xinfoate) 61

Symbicort (budesonide and formoterol) 63

5

Chapter 4 Third-line therapies and beyond:

leukotriene antagonists,

anticholinergics and other drugs 66

Summary 66

Introduction 67

Third-line treatment categories and sales 67

Company market share 69

Brand market share and sales 70

Leukotriene antagonist treatments 74

Brand analysis 75

Singulair (montelukast) 75

Anticholinergic and SABA/anticholinergic treatments 77

Brand analysis 77

Combivent (ipratropium and salbutamol) 77

Atrovent (ipratropium) 79

Spiriva (tiotropium) 80

Chapter 5 Leading players in the

asthma/COPD market 84

Summary 84

Introduction 85

Merck & Co 86

Therapeutic focus 86

Third-line treatment market share 87

Marketed products 88

R&D pipeline 88

GSK 89

Therapeutic focus 89

First and second-line treatment market shares 90

Marketed products 90

R&D pipeline 91

Ariflo 92

Boehringer Ingelheim 93

Therapeutic focus 93

Anticholinergic market share 93

Marketed products 94

Schering-Plough 95

Therapeutic focus 95

Marketed products 95

R&D pipeline 96

6

AstraZeneca 97

Therapeutic focus 97

Marketed products 97

R&D pipeline 98

Novartis 99

Therapeutic focus 99

Marketed products 99

R&D pipeline 100

Xolair (omalizumab) 100

QAB149 101

Sepracor 102

Therapeutic focus 102

Marketed products 102

R&D pipeline 103

Alformoterol 103

Altana 104

Therapeutic focus 104

Marketed products 105

R&D pipeline 105

Alvesco (ciclesonide) 105

Daxas (roflumilast) 106

Index 109

7

List of Figures

Figure 1.1: Estimated relative prevalence of asthma patients by severity, 2003 19

Figure 1.2: Estimated variation in the prevalence of asthma in the US & five major European

markets, 2003 21

Figure 1.3: Estimated prevalence of asthma in the US & 5 major European markets, 2003-201322

Figure 1.4: Estimated variation in the prevalence of COPD in the US & 5 major European

markets, 2003 24

Figure 1.5: Estimated prevalence of COPD in the US & 5 major European markets, 2003-2013 25

Figure 1.6: Estimated proportion of patients presenting with asthma that are correctly diagnosed

by visit 27

Figure 1.7: Typical treatment patterns in the treatment of asthma 29

Figure 1.8: Estimated proportion of patients on leading therapeutic classes of drugs used in the

treatment of asthma by disease severity, 2003 30

Figure 2.9: Development timeline for major asthma/COPD drugs and classes 35

Figure 3.10: Asthma/COPD first/second-line brands by company and type, 2004 46

Figure 3.11: US/European* market share of leading inhaled corticosteroid brands (%), 1999-2003

47

Figure 3.12: US/European* market share of leading inhaled beta-2 agonist brands (%), 1999-2003

48

Figure 3.13: US/European* market share of leading inhaled beta-2 agonist brands (%), 1999-2003

49

Figure 3.14: Serevent SWOT analysis 52

Figure 3.15: Xopenex SWOT analysis 54

Figure 3.16: Ventolin SWOT analysis 55

Figure 3.17: Foradil SWOT analysis 56

Figure 3.18: Flixotide/Flovent SWOT analysis 59

Figure 3.19: Pulmicort SWOT analysis 60

Figure 3.20: Seretide/Advair SWOT analysis 62

Figure 3.21: Symbicort SWOT analysis 64

Figure 4.22: Asthma/COPD third-line brands by company and type, 2004 70

Figure 4.23: US/European* market share of leading leukotriene antagonist brands (%), 1999-2003

71

Figure 4.24: US/European* market share of leading anticholinergic and SABA/anticholinergic

combination products (%), 1999-2003 72

Figure 4.25: Singulair SWOT analysis 76

Figure 4.26: Combivent SWOT analysis 78

Figure 4.27: Atrovent SWOT analysis 79

Figure 4.28: Spiriva SWOT analysis 80

Figure 5.29: Merck’s forecast therapeutic focus, 2003-2010 86

Figure 5.30: GSK’s therapeutic focus, 2003-2010 89

Figure 5.31: Boehringer Ingelheim’s therapeutic focus, 2003 & 2010 93

Figure 5.32: Schering-Plough’s forecast therapeutic focus, 2003-10 95

Figure 5.33: AstraZeneca’s forecast therapeutic focus, 2003-10 97

Figure 5.34: Novartis’ forecast therapeutic focus, 2003-10 99

Figure 5.35: Altana’s forecast therapeutic focus, 2003-10 104

8

List of Tables

Table 1.1: Classification of asthma sufferers according to disease severity 19

Table 1.2: Estimated prevalence of asthma in children and adults across the US & 5 European

markets, 2003 21

Table 1.3: Estimated prevalence of asthma in the US & 5 major European markets, 2003-201323

Table 1.4: Estimated prevalence of adult COPD in the US & 5 major European markets, 2003-

2013 26

Table 1.5: Estimates of the number and proportion of patients receiving asthma treatments by

drug class, 2003 31

Table 1.6: US and European* Sales by Drug Class ($m), 2002-2003 32

Table 2.7: US/European* sales category totals ($m), 2002-2003 36

Table 3.8: US/European* Sales of first and second-line asthma/COPD treatments by category

($m), 2002-2003 44

Table 3.9: First/second-line therapy market share by company and territory (%), 2002-2003 45

Table 3.10: Sales of leading 1st/2nd-line treatments by country ($m), 2002-03 50

Table 3.11: Branded SABA/LABA treatments 51

Table 3.12: Branded ICS treatments 57

Table 3.13: Branded LABA/ICS combination treatments 61

Table 4.14: US/European* Sales of third-line asthma/COPD treatments by category ($m), 2002-

2003 68

Table 4.15: Third-line therapy market share by company and territory (%), 2002-2003 69

Table 4.16: Sales of major branded third-line treatments by country, 2002-03 73

Table 4.17: Major branded leukotriene antagonist treatments 75

Table 4.18: Branded ACh and SABA/ACh treatments 77

Table 5.19: US/European* asthma/COPD market share by company (%), 2002-03 85

Table 5.20: US/European* leukotriene antagonist market share by company (%), 2002-03 87

Table 5.21: US/European* sales of Merck & Co’s marketed asthma/COPD portfolio ($m), 2002-

2003 88

Table 5.22: Projected sales of Merck’s asthma/COPD R&D pipeline ($m), 2007 & 2010 88

Table 5.23: US/European* first/second-line treatment market share by company (%), 2002-200390

Table 5.24: US/European* sales of GSK’s marketed asthma/COPD portfolio ($m), 2002-2003 90

Table 5.25: Projected sales of GSK’s asthma/COPD R&D pipeline ($m), 2007 & 2010 91

Table 5.26: US/European* anticholinergic treatment market share by company (%), 2002-2003 94

Table 5.27: US/European* sales of Boehringer Ingelheim’s marketed asthma/COPD portfolio

($m), 2002-2003 94

Table 5.28: US/European* sales of Schering-Plough’s marketed asthma/COPD portfolio ($m),

2002-2003 96

Table 5.29: Projected sales of Schering-Plough’s asthma/COPD R&D pipeline ($m), 2007 & 2010

96

Table 5.30: US/European* sales of AstraZeneca’s marketed asthma/COPD portfolio ($m), 2002-

2003 98

Table 5.31: Projected sales of AstraZeneca’s asthma/COPD R&D pipeline ($m), 2007 & 2010 98

Table 5.32: US/European* sales of Novartis’ marketed asthma/COPD portfolio ($m), 2002-2003

100

Table 5.33: Projected sales of Novartis’ asthma/COPD R&D pipeline ($m), 2007 & 2010 100

Table 5.34: US/European* sales of Sepracor’s marketed asthma/COPD portfolio ($m), 2002-2003

102

Table 5.35: Projected sales of Sepracor’s asthma/COPD R&D pipeline ($m), 2007 & 2010 103

Table 5.36: Projected sales of Altana’s asthma/COPD R&D pipeline ($m), 2007 & 2010 105

Abstract

Business Insights have teamed up with IMS Health to bring you, ‘The Asthma and COPD Market Outlook: Market analysis of future growth and leading players by sector.’ This unique product offering provides an analysis of changing market conditions and strategic future outlook using the gold standard IMS Health sales data and Business Insights ’ expert analysis, an unrivalled source of pharmaceutical intelligence on the asthma and COPD market. Refresh your asthma strategy with new analysis In terms of revenue, the asthma and COPD therapeutic area historically ranks as the sixth largest single source of sales for the pharmaceutical industry. The outlook for the market is currently strong, driven by strategically sound lifecycle management from the major players in the asthma and COPD area, new product launches and favourable epidemiology. Generic competition will continue to remain the major threat to sales growth in this market. The Asthma and COPD Market Outlook: Market analysis of future growth and leading players by sector, provides detailed analysis of all classes of asthma and chronic obstructive pulmonary disease (COPD) drugs across all major indications. Forecasts are provided over the period 2004-2009,enabling you to identify the market leaders of the future and spot potential opportunities and threats to your market position.

Get Full Details About This Report >>

US: 800.298.5699

Int'l: +1.240.747.3093

advertise with us

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 160,000 market research reports, company profiles and country profiles from over 600 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.